This page reprints a manufacturer label. Everything below in quotation marks is copied from Mupirocin Ointment USP, 2%, published by FDA and retrieved on 2026-09-16. Nothing has been added, reworded or left out of the sections shown. It is the manufacturer’s label, reproduced as published.
This page reprints the FDA label for Mupirocin Ointment USP, 2% by Sun Pharmaceutical Industries, Inc, a mupirocin product labelled for dogs. The sections below are copied from that label without change, with the set id and the date it was retrieved from DailyMed. 1 other stored label carries the same active ingredient and is listed at the end.
The label
Product: Mupirocin Ointment USP, 2%. Manufacturer: Sun Pharmaceutical Industries, Inc. FDA Structured Product Label set id 86248181-cdd7-4eaf-8b1a-ef5c1b301d06. Label effective 2023-09-27. Retrieved 2026-09-16 from the DailyMed animal label release, and readable on DailyMed.
Indications
Mupirocin ointment is indicated for the topical treatment of canine bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and Staphylococcus intermedius .
Dosage and Administration
Prior to treatment, the lesion should be cleansed. Mupirocin ointment should be applied to the affected area twice a day. Apply a sufficient amount of ointment to completely cover the infected area. Maximum duration of treatment should not exceed 30 days.
Contraindications
This drug is contraindicated in animals with a history of sensitivity reactions to any of its components.
Warnings
Because of the potential hazard of nephrotoxicity due to the polyethylene glycol content of the base, care should be exercised when using this product in treating extensive deep lesions where absorption of large quantities of polyethylene glycol is possible. Safety of use in pregnant or breeding animals has not been determined. Mupirocin ointment is not for ophthalmic use.
Adverse Reactions
No adverse reactions have been reported with this product. If a skin reaction such as irritation should occur, treatment should be discontinued and appropriate therapy instituted.
Description
Each gram of mupirocin ointment contains 20 mg of mupirocin in a bland, water-washable ointment base consisting of polyethylene glycol 400 and polyethylene glycol 3350 (polyethylene glycol ointment). Mupirocin is a naturally-occurring, broad-spectrum antibiotic. The chemical name is 9-4-[5S-(2S,3S-epoxy-5S-hydroxy-4S-methylhexyl)-3R,4R-dihydroxytetrahydropyran-2S-yl]-3-methylbut-2(E)-enoyloxy-nonanoic acid. The chemical structure is: Chemical Structure
Other labels for this ingredient
These labels are also stored for the same active ingredient. They are not identical to the one reprinted above, and each is listed by product and set id rather than merged with it.
- Muricin ® (mupirocin ointment) 2%, Dechra Veterinary Products. Set id ded00eb4-5edb-46d6-9f86-460d9de01d0b.
FDA adverse event reports
The FDA Center for Veterinary Medicine publishes the adverse event reports it receives through openFDA. The counts below are the reports naming mupirocin as an active ingredient for each species this label names, as returned on 2026-09-16, coded by the VeDDRA reaction term the reporter chose. Reactions are counted per report, so one report can appear under several terms.
These are counts, not rates. Reporting is voluntary, the number of animals treated is not known, and a widely used product accumulates reports for that reason alone. A report records that an event followed a dose; it does not establish that the product caused it. The counts say nothing about how one product compares with another.
Dogs: 150 reports
| VeDDRA reaction term | Reports |
|---|---|
| Diarrhoea | 19 |
| Vomiting | 17 |
| Lack of efficacy - NOS | 15 |
| Lethargy (see also Central nervous system depression in 'Neurological') | 15 |
| Accidental exposure | 14 |
| Elevated alanine aminotransferase (ALT) | 14 |
| Death by euthanasia | 13 |
| No sign | 13 |
| Other abnormal test result NOS | 13 |
| Anorexia | 12 |
| Elevated serum alkaline phosphatase (SAP) | 10 |
| Abnormal cytology | 9 |
| Abnormal radiograph finding | 9 |
| Behavioural disorder NOS | 9 |
| Leucocytosis NOS | 9 |
Outcome as recorded by the reporter: Ongoing 48; Outcome Unknown 21; Recovered/Normal 16; Died 13; Euthanized 8; Recovered with Sequela 3.
Queries: reports, reactions, outcomes. Dataset: openFDA Animal and Veterinary Adverse Event Reports.
Sources
- Mupirocin Ointment USP, 2%FDA · retrieved 2026-09-16
“Prior to treatment, the lesion should be cleansed.” (Dosage and Administration)
- openFDA Animal and Veterinary Adverse Event ReportsFDA · retrieved 2026-09-16
Related
From Glarda
The note drafted from the consult, with the reference you just read sitting beside it in the shape your record already expects.